To be eligible, products must have received marketing approval in the USA by December 31 of the year preceding the award, but not more than 5 years earlier than December 31 of that year, unless the award is for a new and innovative indication, which must have been added within the previous 5 years. The pharmaceutical, biotechnology, diagnostics and medical device products considered for the Prix Galien USA Award must be FDA approved; provisional approvals are not sufficient.
NOMINATIONS MUST BE SUBMITTED BY MAY 31, 2017
FINALISTS ARE ANNOUNCED AT THE END OF JULY.
THE PRIX GALIEN USA AWARDS CEREMONY WILL TAKE PLACE IN OCTOBER.